share_log

基于癌症和炎症药物乐观前景 诺华制药上调中期销售预期

Novartis AG raises mid-term sales expectations based on optimistic outlook for cancer and anti-inflammatory drugs.

Breakings ·  Nov 21, 2024 09:02

Novartis AG stated that by 2029, the company's revenue will grow at a rate of 6% per year, higher than the previous expectation of 5%. Novartis has raised the peak sales expectations for its drugs Cosentyx, Kisqali, Kesimpta, Pluvicto, and Leqvio, most of which are expected to gain exclusive operation rights in the USA in the 2030s or later.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Comment Comment · Views 340

Recommended

Write a comment
Related Stocks Related Stocks
Symbol Mini Chart Price
Scilex Holding
SCLX
0.347
Organon & Co
OGN
15.440
Novartis AG
NVS
115.570
Amgen
AMGN
324.860
Biogen
BIIB
150.380
Log In for the Full List
Investment Course
Choose stocks based on financial reports
Quickly master financial season learning guidelines
When the financial season comes, company stock prices are the most likely to rise and fall, and many excellent investors will see the financial season as a good
[2025.2] How should NVIDIA's performance be viewed? The key indicator to watch for short-term stock prices is this.
NVIDIA has been one of the best-performing Technology giants in the US stock market over the past two years, and since 2024, its stock price has experienced sig
How to view Tesla's performance in January 2025? Pay attention to these four key points.
It's earnings season for US stocks again. The performance of giant companies not only affects their own stock prices but also influences the overall trend of th

Statement

This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.
OK